Skip to main content

Table 6 Distribution of the number of bone lesions identified by Bone SPECT/CT and FCH PET/CT

From: Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

Lesions Bone SPECT/CT FCH PET/CT
0 89 (77%) 87 (75%)
1 9 (8%) 8 (7%)
2–5 8 (7%) 10 (9%)
>  5 9 (8%) 10 (9%)
  1. Percentages are expressed in relation to the total number of patients. Equivocal bone lesions were classified as negative